Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+and HER2-low breast cancer models

被引：2
|
作者：
Proia, Theresa
Wallez, Yann
Bashi, Azadeh Cheraghchi
Wilson, Zena
Randle, Suzanne
Anderton, Mark
Carroll, Danielle
Rasheed, Zeshaan
Pease, J. Elizabeth
Leo, Elisabetta
Mettetal, Jerome
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-13-18
引用
收藏
页数：3
相关论文
共 50 条
  • [31] EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Li, H.
    Wada, R.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S87 - S87
  • [32] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [34] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Desplas, David
    Mansouri, Imene
    Zureik, Mahmoud
    Di Meglio, Antonio
    Haddy, Nadia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 531
  • [35] The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
    Schreiber, Anna R.
    O'Bryant, Cindy L.
    Kabos, Peter
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1061 - 1069
  • [36] Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers
    Bieth, Claire
    Benderra, Marc Antoine
    Tichoue, Herve Foka
    Houari, Samy
    Hassani, Lamia
    Ghebriou, Djamel
    Seknazi, Lauren
    Barthere, Xavier
    Prebet, Coralie
    De Forceville, Louise
    Lotz, Jean-Pierre
    Gligorov, Joseph
    Jamelot, Mathieu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
    Batista, M. Vaz
    Perez-Garcia, J. M.
    Cortez, P.
    Garrigos, L.
    Fernandez-Abad, M.
    Gion, M.
    Martinez-Bueno, A.
    Saavedra, C.
    Teruel, I.
    Fernandez-Ortega, A.
    Servitja, S.
    Ruiz-Borrego, M.
    de la Haba-Rodriguez, J.
    Martrat, G.
    Perez-Escuredo, J.
    Alcala-Lopez, D.
    Sampayo-Cordero, M.
    Braga, S.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (09)
  • [38] Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez-Castedo, Patricia
    Racca, Fabriccio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez, Adela
    Fernandez-Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer
    Alqam, Anas
    Zakhour, Joud
    Karam, Wissam
    Ashkar, Ryan
    Okut, Hayrettin
    Dakhil, Shaker R.
    Dakhil, Christopher
    Mattar, Bassam Ibrahim
    Koeneke, Travis Lee
    Moore, Dennis Frederic, Jr.
    Moore, Joseph A.
    Van Truong, Phu
    Van Truong, Quoc
    Page, Seth Joel
    Reddy, Pavan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
12345